Table 1.
The percentage of people who reported different adverse events on the male injectable combination contraceptive, the female combination contraceptive (COC), the female intrauterine system (IUS), the female vaginal ring, the female injection, the female patch, and the COC during the 1956 trials.
| Adverse Event Frequency (%) | |||||
|---|---|---|---|---|---|
| Adverse Event | Contraceptive | Men | Women | Sample size | Publication |
| ACNE | Injectable Combination Male Contraceptive | 45.9 | 320 | Behre et al 2016 | |
| COC | 5.1 | 1723 | Ortho Tri-Cyclen Lo (2019) | ||
| IUS | 6.8* | 5091 | Mirena (2017) | ||
| Vaginal Ring | 2.4 | 2501 | NuvaRing® (2017) | ||
| Patch | 2.9 | 3322 | Ortho Evra (2010) | ||
| Injection | 1.2 | >3900 | Depo-Provera (2019) | ||
| LIBIDO DECREASE | Injectable Combination Male Contraceptive | 4.1 | 320 | Behre et al 2016 | |
| COC (1959) | 22 | 830 | Pincus et al 1959 | ||
| Vaginal Ring | 2 | 2501 | NuvaRing® (2017) | ||
| Injection | 5.5 | >3900 | Depo-Provera (2019) | ||
| LIBIDO INCREASE | Injectable Combination Male Contraceptive | 38.1 | 320 | Behre et al 2016 | |
| COC (1959) | 20 | 830 | Pincus et al 1959 | ||
| PELVIC PAIN | Injectable Combination Male Contraceptive | 1.9 | 320 | Behre et al 2016 | |
| COC | 5.6 | 4826 | Ortho Tri-Cyclen (2019) | ||
| COC | 9.2 | 1723 | Ortho Tri-Cyclen Lo (2019) | ||
| IUS | 22.6† | 5091 | Mirena (2017) | ||
| Vaginal Ring | 7.2 | 2501 | NuvaRing® (2017) | ||
| Patch | 8.1 | 3322 | Ortho Evra (2010) | ||
| Injection | 11.2 | >3900 | Depo-Provera (2019) | ||
| WEIGHT GAIN | Injectable Combination Male Contraceptive | 3.8 | 320 | Behre et al 2016 | |
| COC (1959) | 55 | 830 | Pincus et al 1959 | ||
| COC | 2.4 | 1723 | Ortho Tri-Cyclen Lo ) | ||
| Vaginal Ring | 4.9 | 2501 | NuvaRing® (2017) | ||
| Patch | 2.7 | 3322 | Ortho Evra (2010) | ||
| Injection | 37.7 | >3900 | Depo-Provera (2019) | ||
| MOOD CHANGES | Injectable Combination Male Contraceptive | 31.7 | 320 | Behre et al 2016 | |
| COC | 2.2 | 1056 | Yaz (2017) | ||
| COC | 2.3 | 2837 | Yasmin (2017) | ||
| COC | 3.8 | 4826 | Ortho Tri-Cyclen (2019) | ||
| COC | 7.6 | 1723 | Ortho Tri-Cyclen Lo (2019) | ||
| IUS | 6.4† | 5091 | Mirena (2017) | ||
| Injection | 1.5 | >3900 | Depo-Provera (2019) | ||
| Vaginal Ring | 6.4 | 2501 | NuvaRing® (2017) | ||
| Patch | 6.3 | 3322 | Ortho Evra (2010) | ||
| HEADACHE | Injectable Combination Male Contraceptive | 5.3 | 320 | Behre et al 2016 | |
| COC | 6.7 | 1056 | Yaz (2017) | ||
| COC | 10.7 | 2837 | Yasmin (2017) | ||
| COC | 33.6 | 4826 | Ortho Tri-Cyclen (2019) | ||
| COC | 30.5 | 1723 | Ortho Tri-Cyclen Lo (2019) | ||
| IUS | 16.3† | 5091 | Mirena (2017) | ||
| Vaginal Ring | 11.2 | 2501 | NuvaRing® (2017) | ||
| Patch | 21.0 | 3322 | Ortho Evra (2010) | ||
*
Crude incidence per person-years